Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations

Epigenomics. 2015 Aug;7(5):687-90. doi: 10.2217/epi.15.27. Epub 2015 Aug 28.

Authors

Anthony M Barsotti^{1

2}, Michael Ryskin¹, Robert A Rollins¹

Affiliations

¹ Oncology Research Unit, Pfizer Worldwide Research & Development, Pearl River, NY 10965, USA.
² Kadmon Pharmaceuticals, New York, NY 10016, USA.

PMID: 26317265
DOI: 10.2217/epi.15.27

No abstract available

Keywords: EZH2; epigenetic reprogramming; epigenetic therapy; gain-of-function mutations; histone methylation; melanoma; polycomb.

Publication types

Editorial

MeSH terms

Enhancer of Zeste Homolog 2 Protein
Enzyme Inhibitors / therapeutic use
Epigenesis, Genetic*
Gene Expression Regulation, Enzymologic / drug effects
Gene Expression Regulation, Neoplastic / drug effects
Histones / metabolism
Humans
Lysine / metabolism
Methylation / drug effects
Molecular Targeted Therapy / methods
Mutation*
Neoplasms / genetics*
Neoplasms / metabolism
Neoplasms / pathology
Neoplasms / therapy
Polycomb Repressive Complex 2 / antagonists & inhibitors
Polycomb Repressive Complex 2 / genetics*
Polycomb Repressive Complex 2 / metabolism

Substances

Enzyme Inhibitors
Histones
EZH2 protein, human
Enhancer of Zeste Homolog 2 Protein
Polycomb Repressive Complex 2
Lysine